# A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.

> **NCT00206284** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1400 (—)

## Conditions studied

- GERD Without Erosive Esophagitis

## Interventions

- **DRUG:** AZD0865

## Key facts

- **NCT ID:** NCT00206284
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** 2005-04
- **Target enrollment:** 1400 (—)
- **Last updated:** 2013-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206284, "A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00206284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*